The decision to recommend CXL is based on a combination of objective measurements, risk factors, and clinical judgment. Our eye doctors use several tools to assess whether your keratoconus is actively progressing and whether your cornea meets the requirements for treatment.
Your eye doctor uses serial corneal topography maps, which are detailed imaging scans of your corneal shape, taken over a period of roughly 6 to 12 months to identify meaningful changes. Progression is generally defined as confirmed worsening in at least two of the following areas: steepening of the front corneal surface, steepening of the back corneal surface, or thinning at the cornea's thinnest point.
Multiple scans are needed to confirm that changes are real and not caused by variables like dry eye, contact lens warpage, or time-of-day fluctuations. Consistent worsening across two or more exams provides the documentation our eye doctors use to recommend treatment.
For standard epi-off cross-linking, the cornea must be at least 400 microns thick after the outer surface layer (the epithelium) is removed. This minimum thickness is necessary to protect the inner layer of corneal cells, called the endothelium, from ultraviolet light during the procedure.
Corneal thickness is measured before and during the procedure using a technique called pachymetry. If a cornea is close to the lower limit, our surgeons may use a special low-concentration riboflavin solution to temporarily swell the cornea to a safe treatment thickness before proceeding.
In some situations, the risk profile of the patient is strong enough to justify earlier treatment before a full year of topography data is collected. Teenagers with moderate keratoconus, patients with the condition in both eyes, and those with a family history of severe disease may receive a CXL recommendation based on these factors alone.
Our eye doctors weigh the low risk of the procedure against the potentially high cost of waiting. For young patients with clear keratoconus on imaging, allowing an additional year of unchecked progression to accumulate documentation can mean permanent loss of corneal tissue that cannot be replaced.
Recovery from CXL involves a period of corneal remodeling that takes several months to complete. Understanding what is normal during this time helps patients stay informed and avoid unnecessary concern while healing progresses.
Your cornea continues to remodel for months following CXL, and your eye doctor will not evaluate treatment success until at least six months after the procedure. Early fluctuations in your topography readings during this window are a normal part of the healing process and do not indicate that the treatment has failed.
Most patients reach stable measurements somewhere between 6 and 12 months after their procedure. Our eye doctors typically schedule topography scans at 3, 6, and 12 months post-procedure to track corneal shape and confirm that progression has stopped.
CXL successfully halts keratoconus progression in the majority of patients, but a subset continues to worsen despite treatment. Risk factors associated with non-response include younger age at the time of treatment, high levels of corneal astigmatism (irregular curvature), thin corneas, and a history of atopic dermatitis, a form of eczema linked to eye rubbing.
If your cornea shows continued steepening on follow-up scans, our eye doctors may discuss options such as repeat cross-linking, Intacs corneal implants (small ring-shaped inserts placed within the cornea to reshape it), or specialty contact lenses to manage vision while addressing ongoing instability.
Standard epi-off CXL requires removing the outer corneal layer before applying riboflavin drops. A newer technique called epi-on cross-linking leaves the epithelium intact throughout the procedure. In 2025, the FDA approved Epioxa, the first epi-on CXL product cleared for patients 13 years of age and older.
Epi-on CXL can be an option for corneas that are too thin to qualify for the standard technique. It also involves less post-procedure discomfort and a faster visual recovery because the outer corneal surface is not disturbed. Our eye doctors can discuss which approach best fits your corneal thickness, age, and stage of disease.
These are some of the questions patients most often ask when considering the right time to pursue corneal cross-linking.
Most eye doctors recommend postponing CXL during pregnancy. Hormonal changes associated with pregnancy can temporarily alter the shape and hydration of the cornea, which makes it difficult to obtain an accurate baseline and to interpret post-procedure topography reliably. The standard guidance is to wait until several months after delivery before scheduling the procedure, so that your corneal measurements reflect a stable, non-pregnant state. If progression is active and a delay feels risky, discuss the specific tradeoffs with your eye doctor directly.
In most cases, each eye is treated in a separate session scheduled several weeks to months apart. This approach allows you to rely on your untreated eye for daily activities like driving and reading during the recovery period, when vision in the treated eye may be temporarily blurry. Same-day bilateral treatment is sometimes offered in carefully selected cases, and our eye doctors can explain whether that approach might apply to your situation based on your corneal health and lifestyle needs.
There is no strict age cutoff for CXL. Keratoconus tends to slow or stabilize naturally by the mid-30s to 40s in many patients, which sometimes reduces the urgency of intervention in older adults. However, if topography scans confirm that your cornea is still progressing at any age and thickness requirements are met, cross-linking can still be appropriate. Your eye doctor will assess whether the potential benefit of halting further progression justifies the procedure given your current corneal status.
Some patients notice worsening vision, more frequent prescription changes, or increasing halos and glare around lights. However, a meaningful amount of progression can occur without any noticeable change in your daily vision, especially in the early stages. This is why consistent monitoring with corneal topography scans is essential even when you feel your vision is unchanged. Regular appointments allow your eye doctor to catch worsening trends before they advance to a point where options become more limited.
The primary goal of CXL is to stop the cornea from changing further, not to improve your current prescription. Some patients do notice modest vision improvement in the months following their procedure as the cornea undergoes remodeling, but this is not guaranteed and should not be the primary reason for pursuing treatment. Once your cornea has stabilized, your eye doctor will refit your glasses or contact lenses to match your new, stable corneal shape.
A thin cornea does not necessarily mean treatment is off the table. Ask your eye doctor about epi-on cross-linking, which keeps the outer corneal layer intact and can be suitable for corneas that fall below the standard thickness threshold. The FDA-approved epi-on option (Epioxa) has expanded access to treatment for patients who may not have qualified before. Custom riboflavin protocols designed to temporarily swell a thin cornea may also allow standard epi-off CXL to be performed safely, depending on your specific measurements.
At NewView Eye Center, our eye doctors are experienced in evaluating keratoconus at every stage and guiding patients toward timely, appropriate care. Serving patients across Northern Virginia, we offer corneal cross-linking alongside a full range of advanced corneal treatments in a practice built around personalized attention. If you have been diagnosed with keratoconus or have concerns about your corneal health, we encourage you to schedule a consultation so we can review your topography history and help you understand your options before progression advances further.
Find more information about our doctors, services, and technology that keep your eyes healthy and your vision at its best.